Drug Monograph
Piperacillin-Tazobactam (Zosyn)
piperacillin sodium / tazobactam sodium
Pharmacokinetic Profile
Half-Life
0.7–1.2 h (both agents)
Metabolism
Minimal; desethyl piperacillin (minor active metabolite)
Protein Binding
~30% (both agents)
Volume of Distribution
Pip 15–21 L; Tazo 18–35 L
Elimination
Renal: 68% pip, 80% tazo unchanged
Clinical Information
Drug Class
Penicillin / BLI combination
Available Doses
2.25 g, 3.375 g, 4.5 g vials
Route
Intravenous only
Renal Adjustment
Required (CrCl ≤40 mL/min)
Hepatic Adjustment
Not required
Pregnancy
Insufficient human data; no fetal harm in animal studies
Lactation
Pip excreted in milk; tazo unknown; use with caution
Schedule
Prescription only (not scheduled)
Generic Available
Yes
Sodium Content
2.84 mEq (65 mg) Na+ per gram pip
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Intra-abdominal infections (complicated appendicitis, peritonitis) | Adults and pediatric ≥2 months | Monotherapy | FDA Approved |
| Nosocomial pneumonia (moderate to severe) | Adults and pediatric ≥2 months | Combination with aminoglycoside for P. aeruginosa | FDA Approved |
| Skin and skin structure infections (cellulitis, diabetic foot, cutaneous abscesses) | Adults | Monotherapy | FDA Approved |
| Female pelvic infections (postpartum endometritis, PID) | Adults | Monotherapy | FDA Approved |
| Community-acquired pneumonia (moderate severity) | Adults | Monotherapy | FDA Approved |
Piperacillin-tazobactam provides broad-spectrum coverage against many gram-positive, gram-negative, and anaerobic organisms, making it a frequently chosen empiric agent for polymicrobial infections in hospitalized patients. Its activity extends to many beta-lactamase-producing pathogens including E. coli, Klebsiella species, Bacteroides fragilis group, and Staphylococcus aureus (methicillin-susceptible). Coverage of P. aeruginosa is preserved when tazobactam protects piperacillin from chromosomal beta-lactamases, though susceptibility testing is recommended.
Off-Label Uses
Febrile neutropenia — empiric monotherapy: Widely used as empiric monotherapy in febrile neutropenia, supported by multiple randomized trials comparing it to carbapenems with comparable outcomes. Evidence quality: High.
Sepsis / undifferentiated bacteraemia — empiric broad-spectrum cover: Frequently used as an empiric agent for suspected sepsis in emergency and critical care settings, pending culture results. Evidence quality: Moderate.
Ventilator-associated pneumonia: Used as first-line empiric therapy based on international ICU guidelines when risk factors for resistant organisms are low to moderate. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Intra-abdominal infection (complicated appendicitis, peritonitis) | 3.375 g IV q6h | 3.375 g IV q6h | 3.375 g q6h (13.5 g/day) | Infuse over 30 min; duration 7–10 days Covers anaerobes; no metronidazole needed |
| Nosocomial pneumonia (including VAP) — empiric | 4.5 g IV q6h | 4.5 g IV q6h | 4.5 g q6h (18 g/day) | Add aminoglycoside if P. aeruginosa suspected; duration 7–14 days Consider extended infusion (3–4 h) for improved PK/PD |
| Skin and soft tissue infection (cellulitis, diabetic foot) | 3.375 g IV q6h | 3.375 g IV q6h | 3.375 g q6h (13.5 g/day) | Duration 7–14 days depending on clinical response Surgical debridement as indicated |
| Female pelvic infection (endometritis, PID) | 3.375 g IV q6h | 3.375 g IV q6h | 3.375 g q6h (13.5 g/day) | Duration 7–10 days Continue until afebrile 24–48 h |
| Community-acquired pneumonia (moderate) | 3.375 g IV q6h | 3.375 g IV q6h | 3.375 g q6h (13.5 g/day) | Duration 7–10 days Consider IV-to-oral switch at 48–72 h if improving |
| Febrile neutropenia — empiric (off-label) | 4.5 g IV q6h | 4.5 g IV q6h | 4.5 g q6h (18 g/day) | Use higher dose for broader Pseudomonas coverage Extended infusion strategy frequently applied |
Renal Impairment Dosing — Adults
| CrCl (mL/min) | Non-Pneumonia Indications | Nosocomial Pneumonia | Maximum Dose | Notes |
|---|---|---|---|---|
| >40 | 3.375 g q6h | 4.5 g q6h | 18 g/day | No adjustment needed |
| 20–40 | 2.25 g q6h | 3.375 g q6h | 13.5 g/day | Reduce dose |
| <20 | 2.25 g q8h | 2.25 g q6h | 9 g/day | Reduce dose and extend interval |
| Hemodialysis | 2.25 g q12h | 2.25 g q8h | 6.75 g/day | Give 0.75 g supplemental dose after each HD session HD removes 30–40% of dose |
| CAPD | 2.25 g q12h | 2.25 g q8h | 6.75 g/day | No supplemental dose needed |
Pediatric Dosing (≥2 months, ≤40 kg, Normal Renal Function)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Appendicitis / peritonitis (age 2–9 months) | 90 mg/kg IV q8h | 90 mg/kg IV q8h | Adult dose if >40 kg | 80 mg/kg pip + 10 mg/kg tazo per dose Infuse over 30 min |
| Appendicitis / peritonitis (age >9 months) | 112.5 mg/kg IV q8h | 112.5 mg/kg IV q8h | Adult dose if >40 kg | 100 mg/kg pip + 12.5 mg/kg tazo per dose Infuse over 30 min |
| Nosocomial pneumonia (age 2–9 months) | 90 mg/kg IV q6h | 90 mg/kg IV q6h | Adult dose if >40 kg | Higher frequency for pneumonia Add aminoglycoside for Pseudomonas |
| Nosocomial pneumonia (age >9 months) | 112.5 mg/kg IV q6h | 112.5 mg/kg IV q6h | Adult dose if >40 kg | Higher frequency for pneumonia Pediatric renal impairment dosing not established |
Clinical Pearl: Extended Infusion Strategy
Extending the infusion duration to 3–4 hours (rather than the standard 30 minutes) optimizes the time-dependent pharmacodynamics of piperacillin by maximizing the fraction of the dosing interval during which free drug exceeds the MIC (fT>MIC). This approach is increasingly adopted in critical care and has been associated with improved clinical outcomes in observational studies and PK/PD modelling, particularly against organisms with MICs at the upper end of the susceptible range. The FDA has endorsed extended infusion for the susceptible-dose-dependent breakpoint against P. aeruginosa (4.5 g q6h over 3 hours).
Pharmacology
Mechanism of Action
Piperacillin-tazobactam combines two complementary mechanisms. Piperacillin is an extended-spectrum ureidopenicillin that exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) within the bacterial cell wall, inhibiting transpeptidase-mediated cross-linking of peptidoglycan. This disrupts cell wall integrity and leads to osmotic lysis and cell death. Piperacillin has intrinsic activity against a wide range of gram-positive organisms, gram-negative aerobes (including Pseudomonas aeruginosa), and most clinically relevant anaerobes. Tazobactam is a penicillanic acid sulfone that functions as an irreversible, mechanism-based inhibitor of many class A beta-lactamases (including TEM, SHV, and CTX-M enzymes). By inactivating these enzymes before they can hydrolyse piperacillin’s beta-lactam ring, tazobactam restores piperacillin’s activity against beta-lactamase-producing organisms such as E. coli, Klebsiella species, and S. aureus. Tazobactam has minimal intrinsic antibacterial activity on its own.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | IV only; peak concentrations immediately after infusion | No oral formulation; bioavailability considerations do not apply |
| Distribution | Vd: pip 15–21 L, tazo 18–35 L; ~30% protein bound; wide tissue penetration (lung, intestinal mucosa, bile, female reproductive tissues); poor CSF penetration with non-inflamed meninges | Tissue concentrations generally 50–100% of plasma; not suitable as sole agent for CNS infections |
| Metabolism | Pip: minor desethyl metabolite (microbiologically active); Tazo: single inactive metabolite | Minimal hepatic metabolism; no dose adjustment in hepatic impairment |
| Elimination | t½ 0.7–1.2 h (both); pip 68% unchanged in urine; tazo 80% unchanged in urine; also biliary excretion; HD removes 30–40% | Renal dose adjustment essential when CrCl ≤40 mL/min; supplemental dose after hemodialysis |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea | 11.3% | Most common adverse effect; usually mild and self-limiting; distinguish from C. difficile colitis if persistent or bloody |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 7.7% | Transient; manage symptomatically |
| Constipation | 7.7% | May occur alongside diarrhea in different patients; likely multifactorial in hospitalized settings |
| Nausea | 6.9% | Usually mild; slower infusion may help |
| Insomnia | 6.6% | Consider timing infusions to minimize nighttime disruption |
| Rash | 4.2% | Includes maculopapular, bullous, and urticarial forms; monitor for progression to serious cutaneous reactions |
| Vomiting | 3.3% | Often accompanies nausea; usually self-resolving |
| Dyspepsia | 3.3% | May reduce with slower infusion rate |
| Pruritus | 3.1% | Evaluate for allergic aetiology if accompanied by urticaria |
| Fever | 2.4% | Higher incidence in cystic fibrosis patients; distinguish drug fever from infection |
| Candidiasis | 1.6% | Oral or vaginal; consequence of broad-spectrum coverage disrupting normal flora |
| Abdominal pain | 1.3% | Assess for underlying infection if new onset |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Anaphylaxis / anaphylactoid reaction | ≤1% | Minutes to first hour of infusion | Stop infusion immediately; epinephrine, airway management; permanent discontinuation |
| Stevens-Johnson syndrome / TEN | Very rare | 1–4 weeks | Discontinue immediately; dermatology consultation; supportive care in burn unit for TEN |
| DRESS (drug reaction with eosinophilia and systemic symptoms) | Very rare | 2–8 weeks | Discontinue; systemic corticosteroids; monitor liver and renal function |
| Hemophagocytic lymphohistiocytosis (HLH) | Very rare | Variable | Discontinue immediately; hematology referral; investigate for fever, cytopenias, hepatosplenomegaly |
| Nephrotoxicity (especially with vancomycin or in ICU) | FDA PI cites OR 1.7 in older ICU trial; ACORN RCT (2023, n=2,511) found no significant AKI difference vs cefepime | Days to weeks | Monitor renal function; consider alternative beta-lactam in critically ill; avoid pip-tazo + vancomycin combination when possible |
| Clostridioides difficile–associated diarrhea (CDAD) | Uncommon | During therapy to ≥2 months after | Test for C. difficile toxin; discontinue pip-tazo if possible; treat with oral vancomycin or fidaxomicin per guidelines |
| Bleeding manifestations (thrombocytopenia, coagulopathy) | Rare | Usually with prolonged courses or renal impairment | Monitor CBC and coagulation; discontinue if significant bleeding |
| Leukopenia / neutropenia | Rare | Typically after >10 days of therapy | Monitor CBC during prolonged courses; usually reversible upon discontinuation |
| Rhabdomyolysis | Very rare (postmarketing) | Variable | Discontinue; check CK and renal function; aggressive IV hydration |
| Seizures / neuromuscular excitability | Rare; higher risk with renal impairment | Variable; related to high drug levels | Reduce dose; ensure appropriate renal adjustment; benzodiazepines for acute seizure |
| Hepatotoxicity (cholestatic pattern, ALT elevation 6–15%) | ALT elevation common; clinically significant injury rare | 1–6 weeks | Monitor LFTs; discontinue if jaundice or ALT >5x ULN; usually reversible |
Discontinuation
Discontinuation Rates
Monotherapy Trials (Adults)
3.2%
Top reasons: Skin reactions 1.3%, GI effects 0.9%, allergic reactions 0.5%
Nosocomial Pneumonia Trials (+ Aminoglycoside)
11.0% vs 6.5% comparator
Top reasons: Higher rate likely driven by aminoglycoside-related toxicity and greater illness severity
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Skin reactions (rash, pruritus) | 1.3% | Monotherapy trials; evaluate for allergic vs non-allergic causes |
| GI effects (diarrhea, nausea, vomiting) | 0.9% | Monotherapy trials; rarely severe enough to warrant cessation |
| Allergic reactions | 0.5% | Monotherapy trials; includes urticaria and anaphylactoid events |
Managing Diarrhea
Diarrhea is the most frequent adverse effect of piperacillin-tazobactam. In mild cases, treatment can usually be continued with supportive care. However, any watery or bloody diarrhea — particularly onset during or up to two months after stopping therapy — warrants evaluation for C. difficile with toxin assay. Avoid antidiarrheal agents until CDAD has been excluded.
Drug Interactions
Piperacillin-tazobactam undergoes minimal hepatic metabolism and is not a significant inducer or inhibitor of cytochrome P450 enzymes. Its key interactions are pharmacodynamic (additive nephrotoxicity, bleeding risk) and relate to physical incompatibility with aminoglycosides.
Major
Vancomycin
MechanismAdditive nephrotoxicity; mechanism not fully characterised
EffectIncreased incidence of acute kidney injury compared to vancomycin alone or with other beta-lactams
ManagementMonitor renal function closely; consider cefepime or meropenem as alternative beta-lactam partner if vancomycin is required
FDA PI
Major
Methotrexate
MechanismPenicillins reduce renal tubular secretion of methotrexate
EffectElevated methotrexate levels with increased toxicity risk
ManagementMonitor methotrexate levels; consider leucovorin rescue; avoid combination if possible
Lexicomp
Moderate
Aminoglycosides (tobramycin, gentamicin, amikacin)
MechanismIn vitro inactivation of aminoglycosides by piperacillin; physical incompatibility in the same IV line
EffectReduced aminoglycoside efficacy; tobramycin levels significantly lowered in HD patients
ManagementAdminister separately; Y-site co-administration only with amikacin or gentamicin under specific conditions per PI; not compatible with tobramycin via Y-site; monitor aminoglycoside levels
FDA PI
Moderate
Probenecid
MechanismInhibits renal tubular secretion of both piperacillin and tazobactam
EffectProlonged half-life and elevated serum concentrations of both agents
ManagementAvoid co-administration unless benefit clearly outweighs risk
FDA PI
Moderate
Heparin / Oral Anticoagulants (warfarin)
MechanismPiperacillin may impair platelet aggregation and prolong bleeding time
EffectAdditive bleeding risk; prolonged PT/aPTT
ManagementMonitor coagulation parameters more frequently; adjust anticoagulant dosing as needed
FDA PI
Moderate
Vecuronium / Non-depolarizing Neuromuscular Blockers
MechanismPiperacillin may potentiate neuromuscular blockade
EffectProlonged paralysis
ManagementMonitor neuromuscular function; be prepared for extended ventilatory support
FDA PI
Minor
Laboratory Test Interference
MechanismNon-enzymatic reactions with glucose oxidase methods
EffectFalse-positive urine glucose (Clinitest); positive direct Coombs test
ManagementUse enzymatic glucose methods; inform blood bank of therapy
FDA PI
Minor
IV Solution Incompatibilities
MechanismChemical instability in alkaline solutions
EffectDegradation and loss of potency
ManagementDo not mix with sodium bicarbonate; incompatible with Lactated Ringer’s (unless EDTA-containing formulation); do not add to blood products or albumin
FDA PIMonitoring
-
Renal Function
Baseline, then every 2–3 days
Routine Serum creatinine and BUN; especially critical if co-administered with vancomycin or in ICU patients where pip-tazo is an independent risk factor for AKI (OR 1.7) -
CBC with Differential
Baseline; weekly if >7 days
Routine Monitor for leukopenia, neutropenia, thrombocytopenia, and eosinophilia; cytopenias more likely with prolonged courses (>10–14 days) -
Hepatic Function
Baseline; repeat if symptoms
Trigger-based ALT elevations reported in 6–15% of patients; monitor AST, ALT, alkaline phosphatase, bilirubin; discontinue if jaundice develops -
Coagulation
If on anticoagulants or prolonged therapy
Trigger-based PT, aPTT, and platelet count; piperacillin can impair platelet aggregation, particularly in renal impairment -
Electrolytes
Baseline; periodically
Routine Monitor sodium (high Na+ load: 780–1040 mg/day at standard dosing) and potassium (risk of hypokalemia, especially with concurrent diuretics) -
Signs of Allergy / Skin
Each infusion; ongoing
Routine Assess for rash, urticaria, mucosal lesions; any progressive rash warrants discontinuation to exclude SJS/TEN/DRESS -
GI Symptoms
Ongoing; test if bloody/watery diarrhea
Trigger-based Test for C. difficile toxin if diarrhea is severe, persistent, or bloody; can occur up to 2 months post-treatment
Contraindications & Cautions
Absolute Contraindications
- History of serious hypersensitivity (anaphylaxis, angioedema) to piperacillin, tazobactam, any penicillin, or any component of the formulation
- History of serious hypersensitivity to beta-lactamase inhibitors
Relative Contraindications (Specialist Input Recommended)
- History of cephalosporin allergy: Cross-reactivity with penicillins is estimated at 1–2%; specialist assessment and possible graded challenge are recommended for patients with documented severe cephalosporin reactions
- Critically ill patients: Pip-tazo was identified as an independent risk factor for renal failure in a large RCT of ICU patients; consider alternative beta-lactams (meropenem, cefepime) if clinically appropriate
- Prior DRESS or SJS/TEN attributed to a penicillin: Risk of recurrence; avoid re-exposure and consult allergy/immunology
Use with Caution
- Renal impairment (CrCl ≤40 mL/min): Dose reduction is required; monitor for neurotoxicity including seizures at elevated drug levels
- Seizure disorder or CNS pathology: Penicillins may lower seizure threshold, especially at high doses with impaired renal clearance
- Heart failure or sodium-restricted diets: Significant sodium load (up to 1040 mg/day Na+ at full dose); monitor fluid balance and electrolytes
- Patients receiving concurrent anticoagulants: Additive bleeding risk; monitor coagulation closely
- Cystic fibrosis: Higher incidence of drug fever and rash with penicillins in this population
- Elderly patients: Greater likelihood of renal impairment; start at lower end of dosing range and monitor renal function
FDA Safety Communication
Nephrotoxicity in Critically Ill Patients
In a randomized, multicentre, controlled trial of 1,200 critically ill adults, piperacillin-tazobactam was found to be an independent risk factor for renal failure (OR 1.7, 95% CI 1.18–2.43) and was associated with delayed recovery of renal function compared to other beta-lactam agents. The FDA advises that alternative treatment options should be considered in the critically ill population. If pip-tazo is used, renal function should be monitored throughout therapy.
FDA Safety Communication (2024)
Rhabdomyolysis
Postmarketing reports of rhabdomyolysis have been associated with piperacillin-tazobactam use. Clinicians should monitor for signs such as muscle pain, weakness, dark urine, or elevated CK. Therapy should be discontinued and supportive treatment initiated if rhabdomyolysis is suspected.
Patient Counselling
Purpose of Therapy
Piperacillin-tazobactam is a powerful antibiotic given through a vein (IV) to treat serious bacterial infections. It works by killing bacteria and is only effective against bacterial infections, not viral illnesses such as the common cold or flu. It is typically administered in hospital settings.
How to Take
This medication is given by IV infusion, usually over 30 minutes (or longer, as directed by the care team). Each dose is prepared and administered by healthcare professionals. It is important to receive every scheduled dose and to complete the full prescribed course even if symptoms improve, as stopping early may allow resistant bacteria to survive.
Diarrhea
Tell patient
Loose stools are common with this antibiotic and usually resolve once treatment ends. Stay hydrated and inform the nursing team if diarrhea is frequent or bothersome.
Call prescriber
If stools become watery, bloody, or are accompanied by abdominal cramps and fever, even if occurring weeks after the last dose. Do not take anti-diarrhea medication without checking with the care team first.
Allergic Reactions
Tell patient
Mild rash and itching can occur. Inform the care team of any previous antibiotic allergies before the first dose. Most mild reactions can be managed, but the team needs to assess each one.
Call prescriber
Immediately alert nursing staff if experiencing difficulty breathing, throat tightness, facial swelling, widespread hives, or feeling faint during or after the infusion. Any worsening skin rash with peeling, blistering, or mouth sores needs urgent evaluation.
Infusion-Site Reactions
Tell patient
Some redness, swelling, or discomfort at the IV site is possible. The care team can adjust the infusion rate or move the IV line if needed.
Call prescriber
If the area becomes very swollen, painful, warm, or if there is streaking along the vein, notify the nursing team promptly.
Completing the Full Course
Tell patient
It is common to start feeling better before the antibiotic course is finished. However, stopping early increases the risk of the infection returning and of bacteria becoming resistant to treatment.
Call prescriber
If symptoms are not improving after 48–72 hours of treatment, or if new symptoms such as high fever, worsening pain, or confusion develop.
Pregnancy & Breastfeeding
Tell patient
Piperacillin-tazobactam crosses the placenta. Piperacillin is excreted in breast milk in small amounts; the effect of tazobactam on breast milk is not studied. Discuss with the care team if pregnant, planning pregnancy, or breastfeeding.
Call prescriber
If pregnancy is confirmed during therapy, discuss continuation vs alternatives with the treating physician.
Sources
Regulatory (PI / SmPC)
- Zosyn (piperacillin and tazobactam) for injection. Full Prescribing Information. Pfizer/Baxter Healthcare. Revised 2024. FDA Label Primary source for all approved indications, dosing, renal adjustment, adverse reactions, and contraindications cited in this monograph.
- Piperacillin and Tazobactam for Injection. Full Prescribing Information. Civica, Inc. Revised December 2025. DailyMed Current generic label with updated warnings including rhabdomyolysis (2024) and HLH.
- FDA. Rationale for Piperacillin-Tazobactam Breakpoints for Pseudomonas aeruginosa. March 2024. FDA.gov Provides the rationale for the susceptible-dose-dependent breakpoint and endorsement of extended infusion (4.5 g q6h over 3 hours).
Key Clinical Trials
- Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298-1305. doi:10.1164/rccm.201505-0857OC Supports extended/continuous infusion strategy for improved PK/PD targets in critically ill patients.
- Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance (MERINO trial). JAMA. 2018;320(10):984-994. doi:10.1001/jama.2018.12163 Landmark RCT showing meropenem superiority over pip-tazo for ESBL-producing Enterobacterales bloodstream infections.
- Qian ET, Casey JD, Wright A, et al. Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial. JAMA. 2023;330(16):1557-1567. doi:10.1001/jama.2023.20583 Largest RCT (n=2,511) comparing pip-tazo to cefepime; found no significant difference in AKI risk (OR 0.95, 95% CI 0.80–1.13). Note: the FDA PI still cites an earlier 1,200-patient ICU trial (OR 1.7 for renal failure vs other beta-lactams), which remains in the label as a safety warning.
Guidelines
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. doi:10.1093/cid/ciae403 IDSA guidance on when pip-tazo remains appropriate and when to escalate to carbapenems for resistant infections.
- Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and IDSA. Clin Infect Dis. 2010;50(2):133-164. doi:10.1086/649554 Foundation guideline recommending pip-tazo as first-line empiric monotherapy for community-acquired intra-abdominal infections.
Mechanistic / Basic Science
- Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969-976. doi:10.1128/AAC.01009-09 Comprehensive classification of beta-lactamases relevant to understanding tazobactam’s spectrum of inhibition (class A enzymes).
- Perry CM, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57(5):805-843. doi:10.2165/00003495-199957050-00017 Comprehensive pharmacological review covering mechanism, spectrum, clinical efficacy, and tolerability.
Pharmacokinetics / Special Populations
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Piperacillin-Tazobactam. National Institute of Diabetes and Digestive and Kidney Diseases. Updated October 2020. NCBI Bookshelf Provides hepatotoxicity data including ALT elevation rates (6–15%) and reports of DRESS-associated cholestatic injury.
- Abdul-Aziz MH, Lipman J, Akova M, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? J Antimicrob Chemother. 2016;71(1):196-207. doi:10.1093/jac/dkv288 DALI cohort data supporting extended infusion in ICU for improved PK/PD target attainment.